How to Buy Argenx Se Stock
Argenx Se
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China.
Argenx Se stock last closed at $734.35, down 2.39% from the previous day, and has increased 40.62% in one year. It has overperformed other stocks in the Biotechnology industry by 0.89 percentage points. Argenx Se stock is currently +43.97% from its 52-week low of $510.06, and -5.74% from its 52-week high of $779.03.
As of Sep 17, 2025, there are 61.03M ARGX shares outstanding. The market value of ARGX is $44.82B. In the past 24 hours, 417,000 ARGX shares were traded.
How to Buy Argenx Se Stock
Wondering how to invest in Argenx Se stock? Here's how.
- Figure out where to buy Argenx Se stock: You need to choose an online brokerage, but don't worry - we've tested dozens of online brokerages and apps to help you choose where to buy Argenx Se stock.
- Create your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Deposit funds into your investment account: Select your method of payment and add your details.
- Research Argenx Se stock: The Argenx Se ticker symbol is ARGX. Is Argenx Se stock a good investment? Should you buy shares of ARGX? How do ARGX's underlying business fundamentals look? Do top analysts think Argenx Se is a good buy? Why has ARGX's stock price moved recently? (Hint: Our stock research tools can help you figure out if ARGX is a good stock to buy).
- Execute your ARGX trade: Decide if you will purchase ARGX shares at the current market price or use a limit order to buy ARGX shares at a specific price.
- Monitor your investment in ARGX: Create a watchlist to important notifications about your new investment in Argenx Se stock.
Step 1: Figure out where to buy Argenx Se stock
You need a brokerage account in order to access the NASDAQ market and buy ARGX shares.
Our recommended brokerage: eToro
In our opinion, eToro is the best place to buy stocks. Here's why:
- Invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to global markets: From Technology to Energy, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro has a community of more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your share purchase by opening an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've selected your brokerage, the next step is to fill out some personal information so you are able to invest in ARGX today.
How to Start a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal data to open a new trading account.
- Submit your information by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you've opened your account on our top ranked stock app, you can securely and quickly fund your account:
Check out the walkthrough below if you need help transferring money into your new investment account.
Step 4: Research Argenx Se stock
After you have decided on the best place to buy Argenx Se stock, it's very important to evaluate their stock before you invest, so you truly wrap your head around the risk as well as the opportunity.
Argenx Se stock at a glance
Argenx Se Overview
WallStreetZen was built to help part-time investors do better fundamental analysis quickly.
You can see all of the due diligence checks on ARGX's stock page.
What is the fair value of ARGX stock?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge ARGX's true value.
Using relative valuations measures:
- ARGX could be undervalued based on its P/E ratio of 29.35x, relative to Biotechnology industry P/E ratio of -97.28x
- ARGX could be overvalued based on its P/B ratio of 6.25x, relative to Biotechnology industry P/B ratio of 4.69x
- ARGX may be overvalued based on its PEG ratio of 3.96x
You can do additional valuation analysis on ARGX's stock here.
ARGX Financials at a glance
Pros:
- ARGX profit margin has gone up from -615.9% to 78,552% in the past year.
- There are more short-term assets than long-term liabilities on the ARGX balance sheet.
- There are more short-term assets than short-term liabilities on the ARGX balance sheet.
- ARGX has a low debt to equity ratio of 0.18.
- ARGX's operating cash flow of $475.01M allows it to safely service it's debt of $50.77M.
- Total ARGX debt is lower than 5 years ago, relative to shareholder equity.
- ARGX earnings of $785.22M is not sufficient to cover its interest payments.
Do analysts think it's a good time to buy Argenx Se stock
Out of 13 Equities analysts who track ARGX, the consensus analyst rating on Argenx Se is a Strong Buy
It's important to keep in mind that analyst ratings are not stock recommendations, nor are they investment advice.
Latest ARGX Analyst Forecasts
Yatin Suneja, a top 12% analyst from Guggenheim maintains ARGX with a strong buy rating and raises their ARGX price target from $1,060.00 to $1,070.00, on Aug 1, 2025.
Guggenheim's Yatin Suneja raised their price target on Argenx Se (NASDAQ: ARGX) by 0.9% from $1,060 to $1,070 on 2025/08/01. The analyst maintained their Strong Buy rating on the stock.
Argenx SE reported its Q2 2025 earnings.
Suneja described the print as "an impressive performance with results that further underscore the strength of the company's fundamentals."
Earnings Report
For Q2 2025, Argenx SE reported:
- EPS of $3.74, up 731.1% Y/Y.
- Revenue of $949M, up 98.6% Y/Y.
Management did not provide EPS and revenue guidance in its press release.
CEO Tim Van Hauwermeiren commented: “We continue to make meaningful progress towards our Vision 2030, advancing bold innovation that has already reached more than 15,000 patients globally.
“VYVGART is delivering strong growth across all indications, formulations, and regions.
“We are still in the early stages of capturing the full market opportunity in MG and CIDP, with the recent launch of the VYVGART SC prefilled syringe driving demand from new patients and prescribers.
“In MG, we are shaping the market as the fastest growing biologic, moving earlier in the patient treatment paradigm, and working toward the broadest possible label.
“In CIDP, we continue to see consistent patient growth, with ample runway to reach the 12,000 patients in the U.S. who remain inadequately controlled on standard of care.
“This is just the beginning of the larger growth opportunity ahead.
“With six registrational and six proof-of-concept readouts expected by the end of 2026, we are executing on our proven innovation playbook that is delivering pipeline-in-a-product opportunities aimed at transforming care for patients with high unmet need.”
Matthew Harrison, a top 26% analyst from Morgan Stanley maintains ARGX with a strong buy rating and raises their ARGX price target from $700.00 to $766.00, on Aug 1, 2025.
Douglas Tsao, a bottom 13% analyst from HC Wainwright & Co. maintains ARGX with a buy rating and raises their ARGX price target from $720.00 to $774.00, on Aug 1, 2025.
Derek Archila, a top 4% analyst from Wells Fargo maintains ARGX with a strong buy rating and raises their ARGX price target from $741.00 to $756.00, on Jul 31, 2025.
David Nierengarten, a top 9% analyst from Wedbush reiterates ARGX with a buy rating and maintains their ARGX price target from $715.00 to $715.00, on Jun 24, 2025.
You can dig deeper into what analysts are projecting on the Argenx Se stock forecast page.
ARGX Technicals
ARGX Performance Metrics
Last year, ARGX revenue was $1.92M. Over the past five year, ARGX's revenue has increased by -50.87% per year. This was slower than the Biotechnology industry average of 66.41%.
You can research ARGX's earnings and revenue performance here.
Latest Insiders Trades at ARGX
In the last 12 months, insiders at ARGX have not bought or sold any shares.
Dig into more about who owns ARGX shares here.
Does ARGX provide a stable income stream?
No, Argenx Se doesn't provide an income stream by paying out dividends.
Get opinions from other investors
One of the reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other traders have to say.
Step 5: Execute your ARGX trade
There are two main order types:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are mostly fine for most investors. - Limit order: A limit order lets you buy or sell a security at a specific price (or better).
If you want to be certain you're buying or selling at a specific dollar amount limit, use a limit order.
Hit the Open Trade button and your broker will execute the order.
If you want additional help buying stocks on eToro, click the helpful video below:
Step 6: Monitor your investment in ARGX
Now that you own some shares in ARGX, you'll want to keep up with your investment.
Make a watchlist to track the latest developments regarding your ARGX stock.
ARGX Feed
How to Buy Stock in Argenx Se
To reiterate, here are the 6 steps to buy Argenx Se stock:
- Figure out where to buy Argenx Se stock
- Create your brokerage account
- Deposit funds into your investment account
- Research Argenx Se stock
- Execute your ARGX trade
- Monitor your investment in ARGX
If you require a online brokerage, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to get updates on your new investment in Argenx Se, click the button below.
Related Content
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.